Independent register of U.S. FDA drug recalls · updated Oct 14, 2026
RxRecalls Get alerts

FDA Drug Recalls

11,818 recalls · Class II, newest first

Class II · Moderate risk

Doxycycline Hyclate USP

Labeling: Not Elsewhere Classified. Manufacturer and product were discovered to be on FDA Import Alert 66-66 for misbranding of active pharmaceutical ingredient.

Terminated Labeling / mix-up American Pharmaceutical Ingredients LLC D-0927-2017
Class II · Moderate risk

Option 2

Defective Container: Carton is missing the tablet blister strip and tablet.

Terminated Packaging defect L. Perrigo Company NDC 0113-2003-12 D-0887-2017
Class II · Moderate risk

Methocarbamol

CGMP Deviations: Lack of quality assurance at the API manufacturer.

Terminated cGMP deviation American Pharmaceutical Ingredients LLC D-0937-2017
Class II · Moderate risk

Caffeine Powder

Marketed without an Approved NDA/ANDA: The product consists of pure, powdered caffeine and is an unapproved drug due to stimulant claims. The product is also misbranded as it fails to bear adequate directions for its intended use.

Terminated Unapproved drug Global Marketing Enterprises, Inc. D-1096-2017
Class II · Moderate risk

Zenatane (isotretinoin)

Failed Dissolution Specifications: out of specification results observed for low dissolution.

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-137-81 D-0886-2017
Class II · Moderate risk

Zenatane (isotretinoin)

Failed Dissolution Specifications: out of specification results observed for low dissolution.

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-113-81 D-0885-2017
Class II · Moderate risk

Zenatane (isotretinoin)

Failed Dissolution Specifications: out of specification results observed for low dissolution.

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-136-81 D-0884-2017
Class II · Moderate risk

Zenatane (isotretinoin)

Failed Dissolution Specifications: out of specification results observed for low dissolution.

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-135-81 D-0883-2017
Class II · Moderate risk

Saphris 10 mg

Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets

Terminated Labeling / mix-up Forest Laboratories, LLC NDC 0456-2410-60 D-0880-2017

Recalls by year